Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Living Cell Technologies has received 10% ownership of CytoSolv. This is in exchange for restricted supply of choroid plexus cell clusters from its designated pathogen free pig herd and granting CytoSolv a non-exclusive, non-transferable licence to use its broad choroid plexus patents for wound healing.
Subscribe to our email newsletter
CytoSolv is a newly formed Rhode Island biomedical company, developing proprietary technology to address wound healing, initially targeting diabetic ulcers. Its technology involves the delivery of a mixture of wound-healing factors derived from porcine choroid plexus (CP) cells cultured using proprietary techniques. These cells normally secrete a variety of factors into the cerebrospinal fluid that are responsible for growth, differentiation, nurturing and maintenance of the brain.
CytoSolv has demonstrated that a topical gel based on a cocktail of these factors accelerates and improves the quality of healing of open skin wounds. It has recently been awarded $500,000 from the Slater Technology Fund to pursue more advanced pre-clinical development in the year ahead.
Paul Tan, chief executive officer of LCT, said: “Although this collaboration is outside LCT’s core business of live cell implants, the topical use of secreted products from porcine CP cells offers a potential revenue stream from supply of cells and investment return. The experienced team at CytoSolv has produced very promising preliminary data, and we look forward to continuing this exciting collaboration.”